Action Novartis Ag Basel Namen ... (PK) - NVSEF

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

107,92

Prix Achat

104,00

Prix Vente

111,61

Volume échangé

0,00 Fourchette du Jour 0,00

90,24 Plage de 52 semaines 123,55

Cap du marché

228,579B

Clôture Veille

107,92

Ouverture

Dernière Transaction

106.992

Dernière heure de transaction

16:41:46

Volume financier

VWAP

Volume moyen (3 m)

73 569

Actions en circulation

2 118 043 712

Rendement du Dividende

Ratio Cours sur Bénéfices

19,14

Bénéfice par action (BPA)

5,64

Chiffre d'affairess

51,72B

Bénéfice net

11,94B

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.novartis.com

Siège social

Basel, Che

Fondé

Novartis Ag Basel Namen Akt (PK) est coté dans le secteur Pharmaceutical Preparations de la OTCMarkets avec le ticker NVSEF. Le dernier cours de clôture d'Novartis Ag Basel Namen ... (PK) était de US$107,92. Au cours de la dernière année, les actions de Novartis Ag Basel Namen ... (PK) ont été négociées dans une fourchette de prix de US$ 90,24 à US$ 123,55.

Novartis Ag Basel Namen ... (PK) compte actuellement 2 118 043 712 actions en circulation. La capitalisation boursière d'Novartis Ag Basel Namen ... (PK) est de US$228,58 milliard. Novartis Ag Basel Namen ... (PK) a un ratio cours/bénéfice (ratio PE) de 19.14.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	5.42	5.28780487805	102.5	107.92	102.5	758	106.1899912	CS
4	8.048	8.05831464274	99.872	107.92	97.45	171508	104.98997843	CS
12	5.495	5.36490114718	102.425	107.92	94.696	73569	104.22906135	CS
26	-11.08	-9.31092436975	119	123.55	94.696	58723	104.57241333	CS
52	5.01	4.86833155184	102.91	123.55	90.24	46684	104.18670135	CS
156	23.91	28.4608975122	84.01	123.55	72.98	50279	92.43509429	CS
260	11.12	11.4876033058	96.8	123.55	68.65	46216	89.68743813	CS

NVSEF - Frequently Asked Questions (FAQ)

What is the current Novartis Ag Basel Namen ... (PK) share price?

The current share price of Novartis Ag Basel Namen ... (PK) is US$ 107,92

How many Novartis Ag Basel Namen ... (PK) shares are in issue?

Novartis Ag Basel Namen ... (PK) has 2 118 043 712 shares in issue

What is the market cap of Novartis Ag Basel Namen ... (PK)?

The market capitalisation of Novartis Ag Basel Namen ... (PK) is USD 228,58B

What is the 1 year trading range for Novartis Ag Basel Namen ... (PK) share price?

Novartis Ag Basel Namen ... (PK) has traded in the range of US$ 90,24 to US$ 123,55 during the past year

What is the PE ratio of Novartis Ag Basel Namen ... (PK)?

The price to earnings ratio of Novartis Ag Basel Namen ... (PK) is 19,14

What is the cash to sales ratio of Novartis Ag Basel Namen ... (PK)?

The cash to sales ratio of Novartis Ag Basel Namen ... (PK) is 4,42

What is the reporting currency for Novartis Ag Basel Namen ... (PK)?

Novartis Ag Basel Namen ... (PK) reports financial results in USD

What is the latest annual turnover for Novartis Ag Basel Namen ... (PK)?

The latest annual turnover of Novartis Ag Basel Namen ... (PK) is USD 51,72B

What is the latest annual profit for Novartis Ag Basel Namen ... (PK)?

The latest annual profit of Novartis Ag Basel Namen ... (PK) is USD 11,94B

What is the registered address of Novartis Ag Basel Namen ... (PK)?

The registered address for Novartis Ag Basel Namen ... (PK) is PO BOX, BASEL, 4002

What is the Novartis Ag Basel Namen ... (PK) website address?

The website address for Novartis Ag Basel Namen ... (PK) is www.novartis.com

Which industry sector does Novartis Ag Basel Namen ... (PK) operate in?

Novartis Ag Basel Namen ... (PK) operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
ELYSElys BMG Group Inc (CE)	US$ 0,0004 (39 900,00%)	5,1k
YRIVYangtze River Port and Logistics Ltd (CE)	US$ 0,0001 (9 900,00%)	2,39k
SIRCSolar Integrated Roofing Corporation (PK)	US$ 0,0001 (9 900,00%)	12,77M
NXTPNextPlay Technologies Inc (CE)	US$ 0,0001 (9 900,00%)	2,15k
MFLTYMissfresh Ltd (CE)	US$ 0,0001 (9 900,00%)	103
FVTIFortune Valley Treasures Inc (CE)	US$ 0,0015 (-99,40%)	589
EGRNFChina Evergrande Group (CE)	US$ 0,0001 (-99,01%)	5k
FHBCFernhill Beverage Inc (CE)	US$ 0,000001 (-99,00%)	9,5k
AHFDActive Health Foods Inc (CE)	US$ 0,000001 (-99,00%)	500k
BRAVBravada International Limited (CE)	US$ 0,000001 (-99,00%)	188,96k
GTLLGlobal Technologies Ltd (PK)	US$ 0,0002 (-33,33%)	139,08M
RDARRaadr Inc (PK)	US$ 0,00075 (7,14%)	122,01M
RONNRonn Motor Group Inc (PK)	US$ 0,0003 (0,00%)	107,66M
BYOCBeyond Commerce Inc (PK)	US$ 0,0002 (0,00%)	85,78M
AITXArtificial Intelligence Technology Solutions Inc (PK)	US$ 0,00305 (15,09%)	78,57M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Novartis Ag Basel Namen Akt (PK) (NVSEF)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Novartis Ag Basel Namen Akt (PK)

NVSEF Dernières nouvelles

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NVSEF - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Novartis Ag Basel Namen Akt (PK) (NVSEF) Cours

Novartis Ag Basel Namen Akt (PK) (NVSEF)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Novartis Ag Basel Namen Akt (PK)

NVSEF Dernières nouvelles

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NVSEF - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités